Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of
Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M
Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical
equivalence in the treatment of bacterial vaginosis.